Should I Buy VVOS? VVOS 2026 Analysis

Should You Buy Vivos Therapeutics Inc (VVOS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.710

1 Day change

-4.47%

52 Week Range

7.950

Analysis Updated At

2026/01/26

Vivos Therapeutics Inc (VVOS) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows potential in its market focus and has experienced significant revenue growth, the technical indicators are bearish, and there is no immediate positive trading signal or strong momentum to justify a buy. Additionally, the company's financials, while improving, still show negative net income and EPS, which may not align with a beginner investor's risk tolerance.

Technical Analysis

The technical indicators for VVOS are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 24.066, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.993, with key support at 1.737 and resistance at 2.25. These factors suggest a lack of upward momentum.

Options Data

Positive Catalysts

The company has raised $4.64 million through warrant exercises, which will enhance operational funding. Vivos focuses on treating obstructive sleep apnea with FDA-cleared devices, indicating significant market potential. Revenue increased by 75.73% YoY in Q3 2025, showing strong sales growth.

Neutral/Negative Catalysts

The stock is experiencing a pre-market decline of -0.56%, and the broader market (S&P 500) is also down by -0.15%. The MACD and moving averages are bearish, and gross margin dropped by 7.59% YoY. The company remains unprofitable, with a net income of -$5.4 million and negative EPS of -0.49.

Financial Performance

In Q3 2025, revenue increased by 75.73% YoY to $6.78 million, and net income improved by 106.42% YoY to -$5.4 million. EPS improved by 22.50% YoY to -0.49. However, gross margin dropped by 7.59% YoY to 52.38%. While revenue growth is strong, the company remains unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright initiated coverage with a Buy rating and a $7 price target, citing the company's potential for solid sales growth driven by its new business model and initiatives. However, this is a long-term outlook and does not align with current bearish technical indicators.

3 Analyst Rating

Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 5 USD with a low forecast of 2.5 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.790

Low

2.5

Averages

High

Current: 1.790

Low

2.5

Averages

High

H.C. Wainwright

NULL -> Buy

initiated

AI Analysis

2025-11-17

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-17

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Vivos Therapeutics with a Buy rating and $7 price target. Vivos is a commercial-stage medical device company focused on the commercialization of non-surgical treatment of maxillofacial abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders, the analyst tells investors in a research note. The firm expects the company's new business model and initiatives to drive solid sales growth in the coming years.

Alliance Global Partners

Scott Henry

Buy -> Neutral

downgrade

2025-05-20

Reason

Alliance Global Partners

Scott Henry

Price Target

2025-05-20

downgrade

Buy -> Neutral

Reason

Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company's visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company's Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VVOS

Unlock Now

VVOS Should I Buy

VVOS Should I Buy

Should You Buy Vivos Therapeutics Inc (VVOS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch